Aurodox: Antibiotic obtained from a Streptomyces variant considered as possibly effective against Streptococcus pyogenes infections. It may promote growth in poultry.
ID Source | ID |
---|---|
PubMed CID | 135509117 |
CHEMBL ID | 3221419 |
SCHEMBL ID | 687429 |
MeSH ID | M0001343 |
Synonym |
---|
antibiotic x-5108 |
nsc-233989 |
nsc 233989 |
x 5108 |
mocimycin, 1-methyl- |
1-methylmocimycin |
n-methyl kirromycin |
goldinomycin |
aurodox |
MAU , |
goldinodox |
DB04124 |
unii-pgp5rzh64g |
x-5108 |
pgp5rzh64g , |
12704-90-4 |
aurodox [mi] |
CHEMBL3221419 |
SCHEMBL687429 |
(2s)-n-[(2e,4e,6s,7r)-7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-[(1e,3e,5e)-7-(4-hydroxy-1-methyl-2-oxopyridin-3-yl)-6-methyl-7-oxohepta-1,3,5-trienyl]oxolan-2-yl]-6-methoxy-5-methylocta-2,4-dienyl]-2-[(2r,3r,4r,6s)-2,3,4-trihydroxy-5,5-dimethyl-6-[(1e,3z)-penta-1 |
aurodox; 1-methylmocimycin; antibiotic x-5108; goldinodox; goldinomycin |
(2s)-n-[(2e,4e,6s,7r)-7-{(2s,3s,4r,5r)-3,4-dihydroxy-5-[(1e,3e,5e)-7-(4-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-methyl-7-oxohepta-1,3,5-trien-1-yl]tetrahydrofuran-2-yl}-6-methoxy-5-methylocta-2,4-dien-1-yl]-2-{(2r,3r,4r,6s)-2,3,4-trihydroxy-5,5- |
Q27094966 |
DTXSID801043992 |
AKOS040750636 |
HY-118992 |
CS-0078314 |
Aurodox is a linear polyketide natural product that is produced by Streptomyces goldiniensis. Little is known about the biosynthetic gene cluster (BGC) that encodes its production. Aurod Rox is a member of the family of kirromycin antibiotics.
Excerpt | Reference |
---|---|
"Aurodox is a linear polyketide natural product that is produced by Streptomyces goldiniensis, yet little is known about aurodox biosynthesis or the nature of the biosynthetic gene cluster (BGC) that encodes its production." | ( Biosynthesis of Aurodox, a Type III Secretion System Inhibitor from Streptomyces goldiniensis. Braes, RE; Burley, GA; Giard, J; Hoskisson, PA; McHugh, RE; McKean, IJW; Munnoch, JT; Peschke, F; Roe, AJ; Taladriz-Sender, A, 2022) |
"Aurodox is a member of the family of kirromycin antibiotics, which inhibit protein biosynthesis by binding to elongation factor Tu (EF-Tu). " | ( Conformational change of elongation factor Tu (EF-Tu) induced by antibiotic binding. Crystal structure of the complex between EF-Tu.GDP and aurodox. Hilgenfeld, R; Mesters, JR; Palm, GJ; Vogeley, L, 2001) |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1120962 | Inhibition of Escherichia coli T3SS-mediated hemolysis of erythrocytes | 2013 | MedChemComm, Jan-01, Volume: 4, Issue:1 | Small molecules aimed at type III secretion systems to inhibit bacterial virulence. |
AID1873322 | Antibacterial activity against enteropathogenic Escherichia coli | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox. |
AID1873321 | Inhibition of bacterial type III secretion system in enteropathogenic Escherichia coli | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox. |
AID1873323 | Selectivity index, ratio of IC50 for antibacterial activity against enteropathogenic Escherichia coli to IC50 for inhibition of bacterial type III secretion system in enteropathogenic Escherichia coli | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 14 (46.67) | 18.7374 |
1990's | 9 (30.00) | 18.2507 |
2000's | 1 (3.33) | 29.6817 |
2010's | 4 (13.33) | 24.3611 |
2020's | 2 (6.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 30 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |